Dyslipidemia Market Report 2025

The dyslipidemia market size has grown rapidly in recent years. It will grow from $16.31 billion in 2024 to $18.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to factors such as a rising genetic predisposition, an increasingly sedentary lifestyle, the growing consumption of unhealthy diets, an aging population, and escalating obesity rates.

The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth anticipated during the forecast period can be attributed to factors such as advancements in lipid-lowering therapies, increased awareness and screening programs, the rising prevalence of metabolic disorders, higher healthcare expenditure, and the growing prevalence of dyslipidemia. Key trends during this period include advancements in gene therapies, innovations in RNA-based treatments, progress in AI-driven drug discovery, developments in personalized medicine, and advancements in digital health monitoring.

The growing obese population is expected to drive the expansion of the dyslipidemia market. Obesity, characterized by excess body fat that negatively impacts health, is becoming more prevalent due to lifestyle changes that cause prolonged energy imbalances, leading to gradual weight gain and associated health problems. Obesity contributes to dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels, which increase the risk of cardiovascular diseases. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide are affected by obesity, including 2.5 billion adults aged 18 and older. Additionally, 37 million children under five years old were classified as overweight. This rising rate of obesity is a significant driver of the dyslipidemia market.

Leading companies in the dyslipidemia market are focusing on developing advanced combination therapies to improve treatment outcomes, enhance patient adherence, and address multiple lipid imbalances simultaneously. Advanced combination therapies involve using two or more therapeutic agents in a single regimen to improve efficacy, minimize side effects, and target various mechanisms of the disease. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company, announced that its medications NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) were approved by the Food and Drug Administration (FDA), a US government agency. These advanced, non-statin oral treatments are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The updated labels for these drugs allow them to be used alone or in combination with statins, which are commonly prescribed to lower cholesterol. This flexibility is especially beneficial for patients who cannot tolerate statins or prefer non-statin treatment options.

In July 2022, NewAmsterdam Pharma Holding BV, a Netherlands-based biopharmaceutical company focused on treating dyslipidemia, entered into a merger agreement with Frazier Lifesciences Acquisition Corporation. Through this merger, NewAmsterdam aims to develop obicetrapib, a next-generation, low-dose, once-daily CETP inhibitor designed for patients with dyslipidemia who are at high risk for cardiovascular disease. Frazier Lifesciences Acquisition Corporation, a US-based healthcare company, specializes in novel therapeutics.

Major players in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical.

North America was the largest region in the dyslipidemia market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyslipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dyslipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dyslipidemia is a condition in which the levels of lipids (fats) in the blood become abnormal. The goal of managing dyslipidemia is to regulate lipid levels, reduce the risk of cardiovascular diseases, and enhance heart health through a combination of lifestyle changes, medication, and regular monitoring.

The primary treatment options for dyslipidemia include statins, bile acid sequestrants, PCSK9 inhibitors, small interfering RNA (siRNA), cholesterol absorption inhibitors, fibrates, niacins, omega-3 fatty acid derivatives, and others. Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol production in the liver. These treatments are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The dyslipidemia market research report is one of a series of new reports that provides dyslipidemia market statistics, including the dyslipidemia industry global market size, regional shares, competitors with the dyslipidemia market share, detailed dyslipidemia market segments, market trends, and opportunities, and any further data you may need to thrive in the dyslipidemia industry. This dyslipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dyslipidemia market consists of revenues earned by entities by providing services such as diagnosis, lipid profile testing, medical consultations, lifestyle counseling, prescription, and advanced therapeutic interventions for managing abnormal lipid levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyslipidemia market also includes sales of products such as ezetimibe combination drugs, adenosine triphosphate-citrate lyase (ACL) inhibitors, and bempedoic acid combination drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.